# Pizarra — PT-pseudo_dcd61cf9b443 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd61cf9b443
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.215 ng/mL²
  - PSA velocity: 1.64 ng/mL/yr
  - Prior PSA: 7.9 ng/mL
  - Prostate volume: 38.54 mL
  - Months since last PSA: 2
  - DRE findings: Suspicious (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86351734 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD, Chronic kidney disease
  - Problem list / PMHx: COPD, Chronic kidney disease
  - Current medication: ciprofloxacine
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 39 mL. DRE suspicious. csPCa 0.86.

Vitals: weight 63 kg, height 170 cm, BMI 21.8, BP 111/75 mmHg, HR 73 bpm. Smoking: Ex-smoker (37 pack-yr, quit 2012).

Chief complaint: Assessment of a previously confirmed prostate malignancy alongside a continuously increasing PSA profile.

History: Initial evaluation for an elevated PSA occurred in early 2023, leading to active surveillance for a confirmed prostate malignancy. The individual is a 66-year-old retired primary school teacher, currently married but residing independently, with his wife acting as his main appointment liaison. Urinary complaints remain negligible, reflected by an IPSS score of 6, and he sustains a cycling habit of roughly 20 kilometres on two occasions each week. His medical background includes stable COPD and chronic kidney disease with a diminished eGFR, currently addressed via ciprofloxacin therapy. Recent encounters involved vascular surgery for varicose veins alongside a standard gastroenterology surveillance colonoscopy. Outside of urological matters, he experiences occasional mild insomnia but explicitly denies unexplained weight loss, skeletal discomfort, or haematuria. Morning appointments are preferred to align with public transit timetables. He maintains an ex-smoker status, having accumulated 37 pack-years before cessation in 2012.

Physical examination: DRE: The gland exhibits asymmetric enlargement, presenting a firm, irregular nodule within the left peripheral zone that aligns with a suspicious clinical impression. General inspection notes a well-nourished male with stable vital signs, absent palpable lymphadenopathy, and no hepatosplenomegaly. Abdominal palpation remains unremarkable, characterized by a soft, non-tender cavity without bladder distension.

Patient info: retired primary school teacher; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 33 units / week (heavy); exercise Cycling 2x/week, ~20 km; IPSS score: 6/35 (mild LUTS).

Recent other appointments: Vascular surgery — varicose veins consult; Gastroenterology — surveillance colonoscopy.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.22   (95% CI 0.06-0.85)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.0 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=8.3, age=66.0, psad=0.215, dre_ord=2.0, vol=38.54, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (1.64 ng/mL/yr) and the specific PI-RADS 5 score in conjunction with the prior positive biopsy status. It also could not incorporate the details from the mpMRI report, the PSA history trend, or the full laboratory panel, which are crucial for assessing the clinical significance of the findings.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'NO BIOPSY' with a wide interval (0.43 +/- 0.22), placing it in the 'discuss' tier. This wide interval suggests the input data is highly ambiguous. A failure mode is the contradiction between the high csPCa predicted probability (0.86351734) and the DRE finding of 'Suspicious' (which is not explicitly defined as positive/negative). Another failure mode is ignoring the rising PSA trend (PSA 8.3 from 7.9 over 2 months) which suggests progression, potentially overriding the PI-RADS 5 score.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report confirms high-grade features or specific lesion characteristics, it would strengthen the case for biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid increase, it would increase the urgency for a decision.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical context or previous management decisions.
  <document> laboratory results (full panel) -> This could provide context on renal function or other markers relevant to risk stratification.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_dcd61cf9b443", "radiology_report": "Radiology Division | Erasmus MC | 10 January 2025\nStudy: Multiparametric MRI of the prostate\nIndication: Follow-up on previous malignancy workup. Presenting PSA stands at 8.3 ng/mL, building on a prior PI-RADS 5 classification.\nObservations: The gland spans 38.54 mL. A discrete focus measuring roughly 18 x 14 x 12 mm occupies the left peripheral zone, spanning base to mid-gland. T2 sequences highlight pronounced hypointensity there. Diffusion-weighted imaging confirms marked restriction, mirrored by diminished ADC signal. Post-contrast dynamics show brisk, localized enhancement compared to adjacent tissue. Capsular integrity remains intact with no seminal vesicle involvement or nodal enlargement.\nAssessment: PI-RADS 5 lesion within the left peripheral zone. PSAD 0.215 ng/mL/mL. csPCa predicted probability 0.86351734."}

  **psa_trend**
  {"case_id": "PT-pseudo_dcd61cf9b443", "psa_trend": [{"date": "Jan 2023", "val": 5.8}, {"date": "Jan 2024", "val": 3.7}, {"date": "Jan 2025", "val": 8.3}]}

  **previous_notes**
  {"case_id": "PT-pseudo_dcd61cf9b443", "previous_notes": [{"date": "22 Jan 2024", "author": "Dr. C. Peters (GP)", "text": "22 January 2024 - Dr. C. Peters (General Practice): Laboratory results today indicate a PSA concentration of 7.9 ng/mL, continuing an upward trajectory from the 6.2 ng/mL baseline documented in early 2023. A referral to the urology outpatient service has been processed for specialized evaluation and additional imaging. Routine pharmacotherapy will be maintained, with a routine check scheduled for the near future."}, {"date": "21 May 2024", "author": "Dr. C. Peters (GP)", "text": "21 May 2024 - Dr. C. Peters (General Practice): Routine check on the ongoing urological workup. Serum PSA remains at 8.3 ng/mL, with attendance at the planned urology re-evaluation already arranged. Lifestyle factors, including alcohol consumption, were reviewed. Concurrent management of COPD and chronic kidney disease continues without alteration."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_dcd61cf9b443", "laboratory_results": [{"name": "PSA", "val": "8.3 ng/mL", "date": "29 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.71 ng/mL", "date": "29 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "29 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.2 g/dL", "date": "29 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.1 x10^9/L", "date": "29 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "218 x10^9/L", "date": "29 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "128 umol/L", "date": "29 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "29 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "10.4 nmol/L", "date": "29 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "35 U/L", "date": "29 Dec 2024", "flag": ""}, {"name": "LDH", "val": "139 U/L", "date": "29 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion within the left peripheral zone
  PSA velocity of 1.64 ng/mL/yr (rising trend from 7.9 ng/mL two months prior)
  csPCa predicted probability of 0.86351734

  AGAINST sampling this patient now:
  Prior biopsy status: Positive (None · Negative · ASAP/HGPIN · Positive)

WHERE THIS LEANS
  The retrieved evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which directly contradicts the statistical prior suggesting no biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging and concerning clinical trends. The evidence shows a PI-RADS 5 lesion with a PSAD of 0.215 ng/mL/mL, coupled with a rising PSA velocity of 1.64 ng/mL/yr from 7.9 ng/mL two months prior. This finding strongly overrides the prior positive biopsy status, as the new imaging and trend suggest a change in clinical status warranting further tissue sampling.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, psad=important, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
